Pharma-Bio Serv, Inc. (PBSV) Jun 2024 Earnings Report
PHARMA-BIO SERV INC: Investment Report
Overview
Pharma-Bio Serv, Inc. is a compliance and technology transfer services consulting firm that provides technical compliance consulting services to pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. With a market capitalization of $15.61 million, the company has been consistently performing well and has an impressive dividend track record. This report provides an in-depth analysis of the company's financial performance, growth prospects, and news updates, helping investors make informed decisions.
Core Metrics
- Current price: $0.68 USD
- 52-week high: $1.10
- 52-week low: $0.52
- Market Cap: $15.61 million
- P/E Ratio: 22.67
- Earnings per Share: $0.03
- 50-day average: $0.7192
- 200-day average: $0.87895
- Analyst Recommendations: none
Financial Performance
Pharma-Bio Serv, Inc. has reported revenue growth of -0.44% and an operating cash flow of $1.74 million. The company's gross margins and EBITDA margins stand at 0.28851 and 0.02578, respectively. The total cash and free cash flow are $15.89 million and $4.04 million, respectively.
Growth Prospects
Pharma-Bio Serv, Inc. is well-positioned to benefit from the growing demand for compliance and technology transfer services in the pharmaceutical and biotechnology industries. The company's consistent performance and impressive dividend track record make it an attractive option for investors seeking stable returns.
News and Updates
Recent news articles highlight the company's consistent performance, with earnings per share of $0.02 in 2Q 2023, in line with estimates. The company has also announced results for the quarter ended April 30, 2024. Additionally, PharmiWeb reported on the company's quarterly results, and Yahoo Finance published an article on the company's dividend metrics.
Upgrades and Downgrades
There have been no recent upgrades or downgrades for Pharma-Bio Serv, Inc.
Summary
Pharma-Bio Serv, Inc. presents an attractive investment opportunity, given its consistent performance, impressive dividend track record, and growth prospects in the pharmaceutical and biotechnology industries. With a market capitalization of $15.61 million, the company offers a relatively low-risk option for investors seeking stable returns. However, investors should carefully evaluate the company's financial performance, growth prospects, and industry trends before making an investment decision.
Disclosures
The information on this website should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on other content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Under no circumstances should any information provided on this website or social media platforms be construed as an offer soliciting the purchase or sale of any security, nor should it be construed as an offer to provide investment advisory services.